Document:

Manufacturing Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

EXHIBIT 4.9 
 Dated 30th day of September 2009 
 CANCER VAC PTY LTD 

and 
 CELL
THERAPIES Pty. Ltd. 
  
  

MANUFACTURING AGREEMENT 
 for CAN003 
 a Phase IIb trial of CVacTM 

 
  

 TABLE OF CONTENTS 

 

							
	1.	  	 DEFINITIONS AND INTERPRETATION
	  	 	3	  
	2.	  	 APPOINTMENT OF CT
	  	 	9	  
	3.	  	 TERM OF THE AGREEMENT
	  	 	10	  
	4.	  	 PERFORMANCE OF THE SERVICES
	  	 	10	  
	5.	  	 OBLIGATIONS OF CANCERVAC
	  	 	11	  
	6.	  	 INTERFACE WITH CANCERVAC’S USA CONTRACT MANUFACTURER
	  	 	11	  
	7.	  	 INVOICING AND PAYMENT
	  	 	11	  
	8.	  	 APPOINTMENT OF AUTHORISED REPRESENTATIVES
	  	 	12	  
	9.	  	 CONFIDENTIALITY / INFORMATION
	  	 	12	  
	10.	  	 PRIVACY
	  	 	13	  
	11.	  	 INTELLECTUAL PROPERTY
	  	 	13	  
	12.	  	 REVIEW
	  	 	15	  
	13.	  	 INSURANCE
	  	 	15	  
	14.	  	 INDEMNITY
	  	 	16	  
	15.	  	 REPRESENTATIONS AND WARRANTIES
	  	 	16	  
	16.	  	 ETHICS COMMITTEE APPROVAL AND PATIENT CONSENT
	  	 	19	  
	17.	  	 TERMINATION OR EXTENSION
	  	 	19	  
	18.	  	 RELATIONSHIP
	  	 	20	  
	19.	  	 VARIATION
	  	 	20	  
	20.	  	 ASSIGNMENT
	  	 	20	  
	21.	  	 NOTICES TO CANCERVAC
	  	 	20	  
	22.	  	 NOTICES TO CT
	  	 	21	  
	23.	  	 DISPUTE RESOLUTION
	  	 	21	  
	24.	  	 GOVERNING LAW AND JURISDICTION
	  	 	21	  
	25.	  	 ENTIRE AGREEMENT
	  	 	22	  
	26.	  	 NO WAIVER
	  	 	22	  
	27.	  	 REMEDIES CUMULATIVE
	  	 	22	  
	28.	  	 COUNTERPARTS
	  	 	22	  
	29.	  	 SEVERABILITY OF PROVISIONS
	  	 	22	  
	30.	  	 GST GENERAL PRINCIPLES
	  	 	22	  
	31.	  	 CHANGE IN CONTROL & STRUCTURE
	  	 	23	  
	32.	  	 RELEASE OF INFORMATION
	  	 	23	  
	 SCHEDULE 1     THE SERVICES
	  	 	25	  
	 SCHEDULE 2     CHARGES TO BE INCURRED BY CANCERVAC
	  	 	27	  
	 SCHEDULE 3     INSURANCE
	  	 	31	  
	 SCHEDULE 4     TIMETABLE
	  	 	32	  

  
 2/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 THIS AGREEMENT is made the 30th day of September 2009 

BETWEEN 

Cell Therapies Pty Ltd (ABN 15 100 285 916) of Ground Floor, 10 St Andrews Place, East Melbourne, Victoria 3002
(“CT”) 
 AND 
 CANCER VAC PTY LTD (ABN 64 096 859 513) Suite 1, 1233 High Street Armadale Victoria 3143 (“CANCERVAC”) 
 Each a “Party” and collectively, “Parties”. 
 RECITALS 

CT is the commercial manager of the Peter MacCallum Cancer Centre’s Centre for Blood Cell Therapies (“CBCT”). 

CT is a controlled entity of the Peter MacCallum Cancer Centre (“Peter Mac”) and is the entity through which Peter Mac conducts
all commercial arrangements for CBCT. 
 CT has provided CANCERVAC and its parent company PrimaBiomed Limited with consulting
and cGMP compliant manufacturing services including support for a successful IND application for a Phase IIb trial of CVacTM and the successful technical transfer of CANCERVAC’s manufacturing process for CVacTM to a USA contract
manufacturer. 
 CANCERVAC wishes CT to maintain its support of the overall IND Trial program and specifically to perform the
cGMP compliant blood and cell processing requirements for the Australian arm of the IND Trial 
 CANCERVAC owns certain
intellectual property rights necessary or useful to perform the cell processing for CVacTM. 
 CBCT holds TGA Licence
#149827 for human autologous blood and tissue processing which enables it to undertake cell collection and processing under cGMP/cGTP conditions. CT and CBCT have demonstrable skills and experience with clinical trials and cell processing involving
the TGA and FDA regulatory regimes. 
 CANCERVAC will appoint a Clinical Research Organisation (CRO) to manage the trial and CT
are expected to work collaboratively with the appointed CRO, the principal investigators and the nominated CANCERVAC project leaders. 
 Accordingly, CANCERVAC wishes to engage CT to provide the Services pursuant to the terms and conditions contained in this Agreement. 
 IT IS THEREFORE AGREED AS FOLLOWS 
  

	1.	 DEFINITIONS AND INTERPRETATION 

  

	1.1	 Definitions 

 The following definitions apply unless the context requires otherwise: 
 “Affiliate” means any corporation, firm, partnership or other entity which directly or indirectly controls or is controlled by or is under common control 

  
 3/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 with a Party to this Agreement. For the purposes of this definition,
“control” means ownership, directly or through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, fifty percent (50%) or
more of the equity interests in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing
body of a corporation or other entity; 
 “ARCBS” Australian Red Cross Blood
Service-NTS Division at 6th Floor 464 St Kilda Road
Melbourne 3004 
 “Authorised Representative” means the authorised contact person for a party
for all purposes connected with this Agreement. 
 “CANCERVAC Background Intellectual Property
Rights” means any Intellectual Property Rights provided by CANCERVAC for use in the Services or the Project that is owned, licensed to or controlled by CANCERVAC whether provided on or after the Commencement Date including without
limitation CANCERVAC’s Project methods for CVacTM but excluding any Developed Intellectual Property Rights; 
 “CANCERVAC Insurance Policies” means the insurance policies specified as such in Schedule 3 for an amount of not less than the amount stated in Schedule 3; 

“CANCERVAC Supplied Products” means any products supplied by CANCERVAC or its nominee to CT in connection
with the delivery or performance of the Services; 
 “CBCT” means Peter MacCallum Cancer Centre
as represented by the operation unit of the Haematology and Oncology that reports to Professor Miles Prince and under the day to day control of Dr Dominic Wall; 
 “cGMP” means the Code of Good Manufacturing Practice as interpreted and applied by the Australian Therapeutic Goods Administration (“TGA”). 

“cGTP” means the Code of current Good Tissue Practice as interpreted and applied by the FDA; 

“Clinical Protocol” means the specific clinical trial protocol as part of the Project; 

“Commencement Date” means the date of execution of this agreement. 

“Confidential Information” means all confidential information disclosed by one Party to the receiving
Party or otherwise obtained by the receiving Party as a direct or indirect result of this Agreement including information relating to any technology, marketing strategies and/or business of the disclosing Party but does not include information
which: 
  

	 	(a)	 At the time of the disclosure to the receiving Party, was already in the lawful possession of that Party in written form;

  
 4/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(b)	 Is in or comes into the public domain otherwise than by disclosure in breach of this Agreement or any other breach of confidentiality;

  

	 	(c)	 Is independently developed by the receiving Party; or 

 

	 	(d)	 Is obtained lawfully by the receiving Party from a third Party otherwise than by disclosure in breach of an obligation of confidentiality.

 “CSO” Chief Scientific officer of CANCERVAC or Primabiomed Limited

 “CT Background Intellectual Property Rights” means any Intellectual Property Rights provided
by CT for use in the Services or the Project that is owned, licensed to or controlled by CT whether provided on or after the Commencement Date including without limitation the Quality Systems, but excluding any Developed Intellectual Property
Rights; 
 “CT Insurance Policies” means the insurance policies specified as such in Schedule 3
for an amount of not less than the amount stated in Schedule 3; 
 “CVacTM” means an
autologous dendritic cell vaccine the property of CANCERVAC. 
 “Delegate” means a deputy
authorised to act on behalf of an Authorised Representative. 
 “Developed Intellectual Property
Rights” means Intellectual Property Rights acquired, developed or created in relation to the Project, in the course of this Agreement or the provision of the Services, which arises at a date after the Commencement Date of this Agreement;

 “Facilities” means all facilities required by CT to provide the Services pursuant to this
Agreement; 
 “FDA” means the Food and Drug Administration of the USA; 

“Force Majeure” means an event or cause beyond the reasonable control of the Party claiming force majeure
including, without limitation: 
  

	 	(a)	 act of God, lightning, storm, flood, fire, earthquake or explosion, cyclone, tidal wave, landslide, adverse weather conditions;

  

	 	(b)	 strike, lockout or other labour difficulty; 

  

	 	(c)	 act of public enemy, war (declared or undeclared), sabotage, blockade, revolution, riot, insurrection, civil commotion, epidemic;

  

	 	(d)	 the effects of any applicable laws, orders, rules or regulations of any government or other competent authority; 

 

	 	(e)	 breakage or accident or other damage to machinery or equipment; 

 

	 	(f)	 failure of process in the performance of the Services; 

 

	 	(g)	 power interruption or failure, to either or both of mainline power transmission or backup/emergency generator, howsoever caused;

  
 5/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(h)	 unsuitability or unavailability of materials supplied by third parties or CANCERVAC necessary for carrying out the obligations of each Party under
this Agreement 

 “GST” has the meaning given in section 195-1 of the A New
Tax System (Goods and Services Tax) Act 1999 (Cth). 
 “Health Information” means:

  

	 	(a)	 information or an opinion about: 

  

	 	(i)	 the physical, mental or psychological health (at any time) of an individual; or 

 

	 	(ii)	 a disability (at any time) of an individual; or 

  

	 	(iii)	 an individual’s expressed wishes about the future provision of health services to him or her; or 

 

	 	(iv)	 a health service provided, or to be provided, to an individual that is also personal information; or 

 

	 	(b)	 other personal information collected to provide, or in providing, a health service; or 

 

	 	(c)	 other personal information about an individual collected in connection with the donation, or intended donation, by the individual of his or her body
parts, organs or body substances; or 

  

	 	(d)	 other personal information that is genetic information about an individual in a form which is or could be predictive of the health (at any time) of
the individual or of any of his or her descendants. 

 “Health Laws” means the
Health Records Act 2001 (Vic), the Health Privacy Principles contained in Schedule 1 of that Act, and any other statute, regulation or law in Australia or elsewhere which relates to the protection of Health Information and which any of the parties
to this Agreement must observe; 
 “IND Trial” means CANCERVAC’s CAN003 Phase IIb trial of
a nominal x60 patients with ovarian cancer to be run under the FDA’s Investigational New Drug (‘IND’) notification system and the TGA’s Clinical Trial Notification (“CTN”) system; 

“Input Tax Credit(s)” has the meaning given in section 195-1 of the A New Tax System (Goods and
Services Tax) Act 1999 (Cth). 
 “Insolvency Event” means, in relation to a party, any one
or more of the following events or circumstances: 
  

	 	(a)	 being in liquidation or provisional liquidation or under administration; 

 

	 	(b)	 having a receiver, receiver and manager, administrator or liquidator of that person or that person’s property, or anyone else who is in
possession, or has control, of that person’s property to enforce any encumbrance appointed to it or any of its property; 

  
 6/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(c)	 being taken under Section 459F(1) of the Corporations Act to have failed to comply with a statutory demand; 

 

	 	(d)	 being unable to pay its debts or being otherwise insolvent; 

 

	 	(e)	 any analogous event or circumstance under the laws of any jurisdiction; or 

 

	 	(f)	 taking any step or being the subject of any action that is reasonably likely to result in any of the above occurring; 

“Intellectual Property Rights” means and includes all present and future intellectual and industrial
property rights conferred by statute, at common law or in equity, including (without limitation): 
  

	 	(a)	 any patent rights, inventions, patent, copyright, designs, rights in circuit layouts, plant breeder’s rights, trade marks, brand names, domain
names, product names, trade secret, or know-how and other results of intellectual effort in the scientific, technological, bio-technological, industrial, literary or artistic and commercial fields, whether or not registered or capable of
registration; 

  

	 	(b)	 any application or right to apply for registration in respect of those rights; 

 

	 	(c)	 any registration of any of those rights or any registration of any application referred to in item (b); and 

 

	 	(d)	 all renewals and extensions of these rights. 

“Loss of Material” means the loss, damage, destruction, contamination, theft or unsuitability of Material
for its intended purpose; 
 “Material” means all products, by-products, samples, or
intermediates produced, collected, received or stored by CT, its staff, employees, contractors or agents for the purpose of performing the Services and includes without limitation any Product; 

“Minimum Yield” means, in respect of any Product, the minimum yield specified in item 12 of Schedule 2;

 “Personnel” means employees, contractors and subcontractors; 

“Personal Information” means information or an opinion (including information or an opinion forming part
of a database), whether true or not and whether recorded in a material form or not, about a person whose identity is apparent, or can reasonably be ascertained, from the information or opinion; 

“Phase IIb Trial” See “IND Trial”. 

“Privacy Laws” means the Privacy Act 1988 (Cth), the National Privacy Principles contained in Schedule 3
of that Act and any approved Privacy Code (as defined in that Act), that applies to a party to this Agreement, and any other statute, regulation or law in Australia or elsewhere which relates to the protection of Personal Information and which any
of the parties to this Agreement must observe; 

  
 7/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Procedure” means, in respect of any Product, the
manufacturing processes specified for the IND Trial; 
 “Product” means the output of the
manufacturing processes required for the IND Trial (CVacTM); 
 “Project” means the
Australian arm of the IND Trial and the Services described in Schedule 1; 
 “Quality Systems”
means a structured and planned approach to the assurance of the quality of product and services provided based upon those processes outlined in AS/NZS/ISO 9002:1994 which relate to the TGA’s code of GMP/Blood and Blood Components or any
system or process relating to such an approach; 
 “Repeats” means, in respect of any Procedure
for a Product, the number of times such Procedure is to be performed after the first Procedure in the event that the Minimum Yield in respect of such Product is not achieved after conducting the first Procedure; 

“Services” means the services set out in Schedule 1 and any other tasks agreed by the Parties and
includes without limitation all Storage Services; 
 “Services Fees” means all charges specified
in Schedule 2 and includes without limitation all Storage Services Fee; 
 “SOP” means standard
operating procedure as applied to cell manipulation and handling for the manufacture of CVacTM under cGMP conditions, 
 “Storage Services” means, in respect of any Material, the storage services specified in item 11, Schedule 2 or as agreed during the Term. 

“Storage Services Fee” means, in respect of any Storage Services, all charges specified in Schedule 2 or
as agreed during the Term. 
 “Taxable Supply” has the meaning given in section 195-1 of the
A New Tax System (Goods and Services Tax) Act 1999 (Cth). 
 “Taxes” means accommodation
taxes, diesel fuel rebates, financial institutions, duty, debits tax, sales taxes, excise duties, stamp duties and customs duties. 
 “Term” means 12 months beginning on the Commencement Date 
 “TGA” means the Therapeutic Goods Administration; 

“Timetable” means the timetable for provision of the Services as set out in Schedule 4 (to be amended
from time to time as needed by mutual agreement of the Parties) and agreed between the Parties in writing from time to time; and 
 “Trial Manager” that individual or organisation appointed by CANCERVAC to manage the Phase IIb Trial. 
  

	1.2	 Interpretation 

  
 8/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Headings are for convenience only and do not affect interpretation. The
following rules apply unless the context requires otherwise. 
  

	 	(a)	 The singular includes the plural and conversely. 

  

	 	(b)	 A gender includes all genders. 

  

	 	(c)	 If a word or phrase is defined, its other grammatical forms have a corresponding meaning. 

 

	 	(d)	 A reference to a person, corporation, trust, partnership, unincorporated body or other entity includes any of them. 

 

	 	(e)	 A reference to a clause, paragraph, Item, Annexure or Schedule, is a reference to a clause, paragraph or Item of or an Annexure to or a Schedule to,
this Agreement. 

  

	 	(f)	 A reference to an agreement or document (including, without limitation, a reference to this Agreement) is to the agreement or document as amended,
varied, supplemented, novated or replaced except to the extent prohibited by this Agreement or that other agreement or document. 

  

	 	(g)	 A reference to a party to this Agreement or another agreement or document includes the party’s successors and permitted substitutes or assigns
(and, where applicable, the party’s legal personal representatives). 

  

	 	(h)	 A reference to legislation or to a provision of legislation includes a modification or re-enactment of it, a legislative provision substituted for
it and a regulation or statutory instrument issued under it. 

  

	 	(i)	 A reference to writing includes a facsimile transmission and any means of reproducing words in a tangible and permanently visible form.

  

	1.3	 Consents or Approvals 

 If the doing of any act, matter or thing under the Agreement is dependent on the consent or approval of a Party or is within the discretion of a Party, the consent or approval may be given or the
discretion may be exercised conditionally or unconditionally or withheld by the Party in its absolute discretion. 
  

	2.	 APPOINTMENT OF CT 

  

	 	(a)	 CANCERVAC engages CT to be the provider of the Services for the term of this Agreement and CT agrees to carry out the Services.

  

	 	(b)	 CT may subcontract the performance of specialised release testing and ancillary services in delivering the Services or any other obligations under
this Agreement CT agrees to promptly provide on request to CANCERVAC full details of all subcontractors engaged by CT. 

  
 9/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(c)	 CT will be fully liable for the performance of its obligations under this Agreement, irrespective of whether those obligations have been
sub-contracted by CT. 

  

	 	(d)	 CT will procure that any subcontract relating to the obligations set out in this Agreement binds the subcontractor to comply with the terms of this
Agreement to the extent that such terms are relevant to the obligations the subject of the subcontract. Notwithstanding any consent granted by CANCERVAC pursuant to Clause 2(b), CT remains liable for ensuring that the subcontractor complies with its
obligations, and that any work undertaken by a subcontractor conforms with the requirements of this Agreement. 

  

	3.	 TERM OF THE AGREEMENT 

 This Agreement will commence on the Commencement Date and shall terminate after a term of twelve (12) months unless extended or terminated in accordance with Clause 17 

 

	4.	 PERFORMANCE OF THE SERVICES 

  

	 	(a)	 CT must perform the Services in accordance with this Agreement. 

 

	 	(b)	 CT must ensure that the Facilities are cGMP/cGTP compliant in performing all aspects of the Services. 

 

	 	(c)	 Subject to an annual four (4) week plant shut down for maintenance CT shall use its best endeavours to ensure that there is sufficient resource
allocation within the Facilities for the provision of the Services. 

  

	 	(d)	 CT will perform its obligations in accordance with the Timetable. 

 

	 	(e)	 In respect of any Product: 

  

	 	(i)	 CT will perform a first Procedure with the purpose of producing the Minimum Yield for such Product; 

 

	 	(ii)	 if after performing the first Procedure the Product does not achieve the Minimum Yield, CT will perform a Repeat with the purpose of producing the
Minimum Yield for such Product; 

  

	 	(iii)	 if the Minimum Yield is not achieved after CT has performed all Repeats, then CT will be under no further obligation to perform any further
Procedures or Repeats in respect of such Product and nothing in this Agreement will require CT to manufacture such Product. 

  

	 	(f)	 CT is to provide CANCERVAC’s Authorised Representative with copies of all communications with the TGA or any entity that has an authority over
the Project and the associated cell processing. 

  

	 	(g)	 When requested by CANCERVAC or PrimaBiomed Limited CT shall furnish to CANCERVAC a comprehensive written report summarizing the data generated to
date and the status of the project. 

  
 10/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	5.	 OBLIGATIONS OF CANCERVAC 

  

	 	(a)	 In consideration for the performance of the Services, CANCERVAC must pay CT the Service Fees, in accordance with the invoicing and payment schedule
set out in Clause 7. 

  

	 	(b)	 CANCERVAC must, within [ * ] of receiving an invoice from CT for costs and expenses, pay all costs and expenses reasonably incurred by CT in the
course of complying with its obligations under this Agreement which were approved in writing by CANCERVAC prior to incurring the cost or expense. 

  

	 	(c)	 CANCERVAC must ensure that it carries out any of its obligations set out in Schedule 1 to enable CT to perform the Services.

  

	 	(d)	 CANCERVAC is to provide CT’s Authorised Representative with copies of all communications with the TGA or any entity that has authority over
manufacturing for the Phase IIb Trial 

  

	 	(e)	 CANCERVAC must ensure that all CANCERVAC staff or nominees involved in the use of the Services comply with the policies, practices, rules,
procedures and standards of the CBCT Facility provided that CT gives CANCERVAC reasonable notice of the contents of such policies, practices, rules, procedures and standards. 

 

	 	(f)	 CANCERVAC is required to declare if there is any genetically modified organisms to be used as part of the Project. 

 

	 	(g)	 CANCERVAC is required to declare if there is any material of animal origin and its status to be used in the processes involved in the Project.

  

	6.	 INTERFACE WITH CANCERVAC’S USA CONTRACT MANUFACTURER 

CT agrees to maintain a continuous dialogue and exchange of information and collaboration with CANCERVAC’s USA
manufacturer for the IND Trial as an integral component of this Agreement. 
  

	7.	 INVOICING AND PAYMENT 

  

	 	(a)	 CT will invoice CANCERVAC on a calendar month basis in accordance with the fees set out in Schedule 2. 

 

	 	(b)	 Subject to clause 7(c), CANCERVAC will pay correctly rendered invoices within [ * ] of delivery to CANCERVAC’s nominated address for billing by
electronic payment to: 

 Commonwealth Bank of Australia 

Cell Therapies Pty Ltd 
 [ * ] 
  

	 	(c)	 CANCERVAC reserves the right to withhold payment of any invoiced amount which is in dispute. 

  
 11/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	8.	 APPOINTMENT OF AUTHORISED REPRESENTATIVES 

  

	 	(a)	 Both CANCERVAC and CT will appoint one of its staff to be the Authorised Representative of that Party. In the case of CANCERVAC, the Authorised
Representative will be Ms Ginny Raymond, or such other person as advised by CANCERVAC to CT in writing from time to time. In the case of CT, the Authorised Representative will be the Ms Maureen Loudovaris or the CBCT Manufacturing Nominee
(Production Manager) or such other person as advised by CT to CANCERVAC in writing from time to time. Each Authorised Representative may appoint a Delegate by notice in writing to the other party. 

 

	 	(b)	 CT and CANCERVAC must ensure that their Authorised Representatives (or their Delegates) are available for consultation with the other Party as
reasonably required by the other Party and within [ * ] of being requested. 

  

	 	(c)	 CT and CANCERVAC must ensure that their Authorised Representatives (or their Delegates) maintain an open communication with respect to all
communication with the FDA and TGA or any party with authority over the performance of the Services. 

  

	 	(d)	 CT and CANCERVAC must ensure that their Authorised Representatives (or their Delegates) agree to the form and content of external communications
that relate to the performance of the Services. 

  

	9.	 CONFIDENTIALITY / INFORMATION 

  

	 	(a)	 CT must not disclose, and must ensure that CBCT, and CT’s and CBCT’s employees, contractors and agents do not disclose, any Confidential
Information of CANCERVAC to any third party, unless the disclosure is required by law. If disclosure is required by law, CT must immediately provide written notice to CANCERVAC’s Authorised Representative of the requirement for the disclosure
of the Confidential Information and use its reasonable endeavours to withhold any such disclosure for at least [ * ]. 

  

	 	(b)	 CT warrants that all relevant employees of CT and CBCT have entered into written confidentiality agreements undertaking confidentiality obligations
no less onerous than those of CT under this Agreement. On receipt of a request from CANCERVAC, CT covenants to provide copies of the confidentiality agreements. 

 

	 	(c)	 CANCERVAC, must not disclose, and must ensure that their Affiliates, and CANCERVAC’s and their Affiliates’ employees, contractors and
agents do not disclose, any Confidential Information of CT to any third party, unless the disclosure is required by law. If disclosure is required by law, CANCERVAC must immediately provide written notice to CT’s Authorised Representative of
the requirement for the disclosure of the Confidential Information and use its reasonable endeavours to withhold any such disclosure for at least [ * ]. 

 

	 	(d)	 Each Party agrees that any disclosure of another Party’s Confidential Information to any of its employees, consultants, Affiliates, licensees
and sub-licensees shall be made only if and to the extent necessary to 

  
 12/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	 
carry out its rights and responsibilities under this Agreement, and shall be limited to the maximum extent possible consistent with such rights and responsibilities and shall only be made to
persons who are bound by written confidentiality obligations to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement. 

 

	 	(e)	 Failure to observe the obligations contained in this Clause is a serious breach and may cause irreparable damage to the relevant Party. In addition
to any other remedies available to the relevant Party for disclosure of Confidential Information, the proprietor of the Confidential Information may require the permanent removal of the person who disclosed the Confidential Information from any
activities associated or connected with this Agreement. 

  

	 	(f)	 This Clause survives the termination of this Agreement. 

 

	 	(g)	 CANCERVAC have at any time the right to inspect all papers and all records and data concerning the Project, including without limitation all
relevant SOPs and documents concerning manufacturing licenses and to make copies of them. 

  

	10.	 PRIVACY 

  

	 	(a)	 Where a Party (Discloser) provides Personal Information or Health Information to another Party (Recipient) the Recipient will:

  

	 	(i)	 comply with the Privacy Laws; 

  

	 	(ii)	 comply with the Health Privacy Laws; 

  

	 	(iii)	 to the extent permitted by law, not in any way respond to a request for access to Personal Information or Health Information, except to refer the
enquirer to the Discloser and to notify the Discloser of the request; and 

  

	 	(iv)	 without limiting the operation of clause 10(a)(ii), the Recipient must: 

 

	 	A).	 only use Personal Information and Health Information for the purpose of this Agreement and not for its own purpose; 

 

	 	B).	 only disclose Personal Information or Health Information if it is necessary for the purpose of this Agreement or with the prior written consent of
the Discloser; and 

  

	 	C).	 ensure that only authorised personnel have access to Personal Information and Health Information and that all Personal Information and Health
Information is stored securely and is protected from unauthorised access, use or disclosure. 

  

	11.	 INTELLECTUAL PROPERTY 

  

	 	(a)	 Nothing in this Agreement will cause the transfer of any rights in, or grant any rights to, the CANCERVAC Background Intellectual Property

  
 13/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	 
Rights, nor the CT Background Intellectual Property Rights to another Party, other than those rights conferred pursuant to Clause 11(c) and (e). 

 

	 	(b)	 Subject to Clause 11(a), all Developed Intellectual Property Rights will vest solely and absolutely in CANCERVAC immediately upon creation and CT
hereby assigns to CANCERVAC all its current and future right, title and interest in and to Developed Intellectual Property Rights. 

  

	 	(c)	 For the avoidance of doubt, CANCERVAC acknowledge that the CT Background Intellectual Property Rights are Confidential Information of CT and remain
the property of CT. CT grants a non-exclusive, perpetual, royalty free licence to CANCERVAC to use the CT Background Intellectual Property Rights for purposes associated with this Agreement, for the purpose of the Project and for the purpose of and
to the extent required for CANCERVAC to use and exploit the CANCERVAC Background Intellectual Property Rights, the Developed Intellectual Property Rights and any modifications or improvements of such Intellectual Property Rights.

  

	 	(d)	 For the avoidance of doubt, CT acknowledges that the CANCERVAC Background Intellectual Property Rights are Confidential Information of CANCERVAC and
remain the property of CANCERVAC (as the case may be). 

  

	 	(e)	 CANCERVAC grant to CT a non-exclusive license to use those Intellectual Property Rights of CANCERVAC as are necessary for the sole purpose of and
only to the extent required to carry out the Services. 

  

	 	(f)	 CT has not made and does not by entering into this Agreement make any representation or warranty, express or implied, that the Services does not
infringe any third party’s Intellectual Property Rights. 

  

	 	(g)	 Any improvements to CANCERVAC Background Intellectual Property Rights will vest in CANCERVAC and any improvements to CT Background Intellectual
Property Rights will vest in CT. The parties agree that improvements to CANCERVAC Background Intellectual Property Rights or to CT Background Intellectual Property Rights do not and will not include Developed Intellectual Property Rights.

  

	 	(h)	 All data resulting from the Services and any Intellectual Property Rights in that data will vest in CANCERVAC, and CT hereby assigns to CANCERVAC
all its current and future right, title and interest in and to the data resulting from the Services and all of its Intellectual Property Rights in that data. 

 

	 	(i)	 Subject to the confidentiality obligations in Clause 9, CT will provide access during the course of this Agreement to CANCERVAC’s employees,
contractors and agents to Confidential Information and to information and materials that contain the CT Background Intellectual Property Rights. CT agrees to CANCERVAC’s unrestricted use and application of any CT Background Intellectual
Property Rights acquired as a result of entering into this Agreement for the purpose defined in this Agreement. If CANCERVAC wish to exploit the CT Background 

  
 14/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	 
Intellectual Property Rights other than in conjunction with their own intellectual property, CANCERVAC will pay a reasonable fee to CT for such usage. 

 

	 	(j)	 Where requested by CANCERVAC, CT must, in relation to moral rights in works as defined as Part IX of the Copyright Act created in the course of
providing the Services (Works), secure from any of its employees, contractors or agents who perform any of the Services, written waivers in respect of any moral rights which may subsist in the Works. CT must ensure that the consent is
genuinely given and not obtained by duress or by the making of any false or misleading statement. 

  

	 	(k)	 Clause 12 survives the termination of this Agreement. 

 

	 	(l)	 Both Parties will execute all documents and do all things reasonably necessary to give effect to the above and to protect all Intellectual Property
Rights arising as a result of this Agreement. 

  

	12.	 REVIEW 

  

	 	(a)	 Where the Term exceeds twelve (12) months, the Parties will conduct an annual review of the obligations of each of the Parties under this
Agreement to ensure the adequacy of the Services. This review will be conducted by the Parties’ Authorised Representatives within thirty (30) days of the anniversary of the Commencement Date or at a time mutually agreed in writing.

  

	 	(b)	 If the Parties’ Authorised Representative decides that the obligations of either Party under the Agreement should be altered, the Parties’
Authorised Representatives will negotiate in good faith appropriate revision of the Services and adjustments (either up or down) to the fees payable to CT under Schedule 2. 

 

	 	(c)	 If the Parties’ Authorised Representatives agree to amendments under this clause, the Parties must amend this Agreement in accordance with
Clause 19 

  

	 	(d)	 If the Parties’ Authorised Representatives cannot agree in relation to any changes to be made pursuant to this clause, the dispute must be
referred to dispute resolution in accordance with Clause 23 

  

	13.	 INSURANCE 

  

	 	(a)	 It is a condition precedent to the operation of this Agreement that CANCERVAC must take out and maintain the CANCERVAC Insurance Policies during the
Term 

  

	 	(b)	 It is a condition precedent to the operation of this Agreement that CT must take out and maintain the CT Insurance Policies during the Term.

  

	 	(c)	 Upon reasonable request of a Party, the requested Party must produce documentary evidence that the insurance required under the Agreement is current
and effective. 

  

	 	(d)	 If a Party cannot or does not comply with its obligation to effect insurance, any other Party may (but is not obliged to) affect such

  
 15/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	 
insurance at the expense of the uninsured Party. Any such expense must be reimbursed within [ * ] of the supply of an invoice. 

 

	14.	 INDEMNITY 

  

	14.1	 CANCERVAC continually indemnify CT, its officers, employees and agents against any claim or proceedings made, threatened or commenced, and any
liability, loss, damage or expense (including consequential loss or damage, damage to real, personal or intellectual property, CANCERVAC data loss or corruption, Loss of Material, personal injury including death and legal costs on a full indemnity
basis) under statute or common law which CT incurs or suffers as a direct or indirect result of any breach by CANCERVAC of this Agreement, or warranties contained in this Agreement or the use by CT of CANCERVAC-supplied human blood or tissue product
which fails to comply with relevant regulatory standards in the provision of the Services. This indemnity does not apply to the extent that such loss or damage is caused by the negligence, act or omission of CT or CBCT. This indemnity survives the
termination of this Agreement indefinitely. 

  

	14.2	 Without limitation to clauses 15(h) and 17(d), CANCERVAC acknowledges and agrees that there exist risks associated with cryopreservation and
refrigeration of the Materials and storage of any Materials in the provision of the Storage Services including without limitation failure howsoever arising of any CT cryogenic or low temperature storage facilities used in the performance of the
Storage Services, any failure by CT to recover any Material, or any loss in yield when any Material is recovered, after having been cryogenically frozen or refrigerated. CANCERVAC further acknowledges and agrees that CT, its officers, employees and
agents will not be liable for any claim or proceedings made, threatened or commenced, or any liability, loss, damage or expense, Loss of Material, personal injury including death and legal costs (on a full indemnity basis) under statute or common
law which arises as a direct or indirect result of any negligence, act or omission of CT under this Agreement. Notwithstanding anything else in this Agreement, CANCERVAC hereby indemnifies and will continue to indemnify CT, its officers, employees
and agents against any claim or proceedings made, threatened or commenced, and any liability, loss, damage or expense, Loss of Material, personal injury including death and legal costs on a full indemnity basis) under statute or common law which
arises as a direct or indirect result of any negligence, act or omission of CT. This indemnity survives the termination of this Agreement indefinitely. 

 

	15.	 REPRESENTATIONS AND WARRANTIES 

  

	 	(a)	 CANCERVAC and CT each represent and warrant as follows: 

 

	 	(i)	 Organization. It is a corporation duly organized, validly existing and is in good standing under the laws of its respective jurisdiction, is
qualified to do business and is in good standing as a corporation in each jurisdiction in which the performance of its obligations hereunder requires such qualification and has all requisite power and authority, corporate or otherwise, to conduct
its business as now being conducted, to own, lease and operate its properties and to execute, deliver and perform this Agreement. 

  
 16/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(ii)	 Authorization. The execution, delivery and performance by it of this Agreement have been duly authorized by all necessary corporate action and do
not and will not (a) require any consent or approval of its stockholders or shareholders or (b) violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect
having applicability to it or any provision of its charter documents or constitution. 

  

	 	(iii)	 Binding Agreement. This Agreement is a legal, valid and binding obligation of it enforceable against it in accordance with its terms and conditions.

  

	 	(iv)	 No Inconsistent Obligation. It is not under any obligation to any person, or entity, contractual or otherwise, that is conflicting or inconsistent
in any respect with the terms of this Agreement or that would impede the diligent and complete fulfilment of its obligations. 

  

	 	(b)	 CT warrants that: 

  

	 	(i)	 it has the expertise, resources (including without limitation financial resources), capacity, experience and ability to perform its obligations
under this Agreement; 

  

	 	(ii)	 it has adequate insurance policies and financial resources to sustain any potential liability incurred in relation to this Agreement;

  

	 	(iii)	 it holds and will at all relevant times hold, and ensure that its subcontractors hold, all necessary licences and authorities legally required to
perform the Services; 

  

	 	(iv)	 the conduct of the Services will be of high quality and provided in a professional manner, with all due care, skill and attention and CT will use
its reasonable endeavours to perform the Services in accordance with industry best practice on the understanding always that in respect of the provision of any Storage Services under this Agreement, CT will use the procedures and equipment it would
customarily use for its own cGMP; 

  

	 	(v)	 it will perform its obligations in a timely and efficient manner; 

 

	 	(vi)	 CT warrants compliance of the Services with GMP/TGA requirements in all circumstances where: 

 

	 	A).	 CT has control over the manufacturing processes; or 

 

	 	B).	 CT controls the status of its starting material. 

  

	 	(vii)	 Where CT does not control the status of its starting material, CT only warrants that its own services comply with GMP/TGA requirements;

  

	 	(viii)	 CT warrants that the Aphaeresis facilities at Peter Mac (which are controlled by the CBCT) are GMP/TGA compliant; and 

  
 17/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(ix)	 CBCT or any subcontractor retained by CT has or will have all licences necessary to perform the obligations under this agreement.

  

	 	(c)	 CANCERVAC warrants that it will undertake a cryopreservation risk analysis and will consider, and adopt where it so decides, any option available
for split storage, including off-site storage. CT agrees to provide reasonable non-financial assistance to CANCERVAC in undertaking such analysis. In the event that CANCERVAC intends to effect insurance policies in respect of stored Materials, CT
will, at no cost to CANCERVAC provide reasonably non-financial support to CANCERVAC to effect an application for such insurance, and where requested by CANCERVAC provide CANCERVAC reasonable site inspections and reasonable access to validation
records by insurance company representatives. 

  

	 	(d)	 CANCERVAC certifies that the CANCERVAC-supplied products have been screened in accordance with the relevant Australian regulations and standards and
warrant to the best of their knowledge and belief that the CANCERVAC-supplied products do not contain any contaminants, viruses, bacteria or other potentially dangerous material. 

 

	 	(e)	 CT agrees to actively participate and co-operate in any TGA audit of the Services and to defend any allegation that CT’s deliverables do not
comply with GMP/TGA requirements. 

  

	 	(f)	 Notwithstanding anything else in this Agreement or otherwise, to the fullest extent permitted by law, none of CANCERVAC or CT will be liable with
respect to any subject matter of this Agreement under any contract, negligence, strict liability or other legal or equitable theory for any indirect, incidental, consequential damages or lost profits. 

 

	 	(g)	 CANCERVAC acknowledges that, without limitation to clause 15(h), CT makes no warranties that in the performance of the Services CT will achieve the
Minimum Yield in respect of the manufacture of any Product. 

  

	 	(h)	 To the full extent permitted by the laws of the Commonwealth of Australia or of any State or Territory of Australia having jurisdiction, any
conditions or warranties imposed by such legislation are excluded. In so far as liability under or pursuant to such legislation may not be excluded or the liability relates to conditions or warranties provided pursuant to this Agreement, such
liability is limited, at the option of CT, to: 

  

	 	(i)	 in respect of Storage Services, the payment of the amount of the Storage Services Fee actually paid in respect of the applicable Material; or

  

	 	(ii)	 in respect of Services other than Storage Services, 

 

	 	A).	 the re-performance of the relevant Services; or 

  

	 	B).	 the payment of the cost of having the relevant Services re-performed and in all circumstances the liability of CT is

  
 18/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	 
limited to the amount of the Services Fees actually paid for the relevant Service pursuant to this Agreement. 

 

	16.	 ETHICS COMMITTEE APPROVAL AND PATIENT CONSENT 

 

	 	(a)	 CT warrants that it will, if necessary, seek approval to provide the Services from the CBCT Ethics Committee, in accordance with the relevant
NH&MRC Guidelines. 

  

	 	(b)	 CANCERVAC warrants that it will ensure that all consent required to be obtained by law from patients in order for CT to perform the Services is
obtained. CANCERVAC will ensure that copies of such consents are provided to CT within [ * ] of CT requesting a copy. 

  

	17.	 TERMINATION OR EXTENSION 

  

	 	(a)	 This Agreement will terminate if 

  

	 	(i)	 CANCERVAC gives [ * ] prior notice in writing of such termination to CT; or 

 

	 	(ii)	 Either Party reasonably determines that the Project is not scientifically or ethically viable; or 

 

	 	(iii)	 CT gives [ * ] prior notice in writing of such termination to CANCERVAC. 

 

	 	(b)	 CANCERVAC may immediately terminate this Agreement by giving written notice to CT if CT: 

 

	 	(i)	 commits a breach of any of the provisions of this Agreement which is incapable of being remedied to the reasonable satisfaction of CANCERVAC;

  

	 	(ii)	 for any reason whatsoever becomes incapable, in the reasonable opinion of CANCERVAC, from performing its obligations under this Agreement;

  

	 	(iii)	 fails to remedy, to the reasonable satisfaction of CANCERVAC, a breach or default of any of the provisions of this Agreement which is, in the
opinion of CANCERVAC, capable of being remedied, within [ * ] of receiving a notice from CANCERVAC of that breach or default; or 

  

	 	(iv)	 is the subject of an Insolvency Event. 

  

	 	(c)	 CT may immediately terminate this Agreement by giving written notice to CANCERVAC if CANCERVAC: 

 

	 	(i)	 commits a breach of any of the provisions of this Agreement which is incapable of being remedied to the reasonable satisfaction of CT;

  

	 	(ii)	 fails to remedy, to the reasonable satisfaction of CT a breach or default of any of the provisions of this Agreement which is, in the

  
 19/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	 
opinion of CT, capable of being remedied, within [ * ] of receiving a notice from CT of that breach or default; or 

 

	 	(iii)	 is the subject of an Insolvency Event. 

  

	 	(d)	 A Party is not liable for any failure or delay in performance of any obligations under this Agreement, including (but not limited to) Loss of
Material, if all of the following conditions are satisfied: 

  

	 	(i)	 the failure or delay arose from Force Majeure; and 

 

	 	(ii)	 the Party took all reasonable precautions against that Force Majeure and did its best to limit its consequences. This does not require the Party to
settle a labour dispute if, in the Party’s opinion, that is not in its best interests; and 

  

	 	(iii)	 the Party gave the other Parties notice of the Force Majeure as soon as practicable after becoming aware of it. 

 

	 	(e)	 If the Force Majeure and the resulting failure or delay lasts for more than [ * ] then the Parties will negotiate in good faith to overcome any
difficulties associated with the Force Majeure. 

  

	 	(f)	 If the Force Majeure and the resulting failure or delay lasts for more than [ * ] then any Party may terminate the Agreement.

  

	 	(g)	 The Term can be extended if the Parties agree in writing to the terms and conditions to apply to the extension prior to the termination date.

  

	 	(h)	 Despite any other provision of this Agreement, 9, 10, 13, 14, 23, 24 and this Clause 17(h) survives the expiry or termination of this Agreement.

  

	18.	 RELATIONSHIP 

 The relationship of the Parties is that of independent contractors and nothing in this Agreement constitutes any Party, the employee, partner, agent, fiduciary, representative, trustee or joint venture of
the other. No Party is liable for an act or omission of another Party except to the extent set out in this Agreement. 
  

	19.	 VARIATION 

 This Agreement can only be varied by the Parties in writing and signed by or on behalf of all Parties. 
  

	20.	 ASSIGNMENT 

 CT may not assign any of its rights and obligations under this Agreement without the written consent of CANCERVAC, which consent must not be unreasonably withheld. 

 

	21.	 NOTICES TO CANCERVAC 

  

	 	(a)	 Any notice required to be given to CANCERVAC under this Agreement must be in writing and may be served: 

 

	 	(i)	 by giving the notice personally to a Director of CANCERVAC; or 

  
 20/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	(ii)	 by delivering the notice for a Director of CANCERVAC at his usual office in Australia; or 

 

	 	(iii)	 by delivering the notice to CANCERVAC’s registered office in Australia. 

 

	 	(b)	 The notice is served at the time it is given or delivered. 

 

	 	(c)	 Electronic transmission of Notices by telefax or email may be used however written acknowledgement of receipt must be received by the transmitting
party. 

  

	22.	 NOTICES TO CT 

  

	 	(a)	 Any notice required to be given to CT under this Agreement must be in writing and may be served: 

 

	 	(i)	 by giving the notice personally to the Managing Director of CT; or 

 

	 	(ii)	 by delivering the notice for the Managing Director of CT at his usual office; or 

 

	 	(iii)	 by delivering the notice to CT’s registered office. 

 

	 	(b)	 The notice is served at the time it is given or delivered. 

 

	 	(c)	 Electronic transmission of Notices by telefax or email may be used however written acknowledgement of receipt must be received by the transmitting
party. 

  

	23.	 DISPUTE RESOLUTION 

 If a dispute arises in relation to this Agreement, any Party may give the other Parties a notice requiring that an attempt be made to resolve the dispute. The Parties will try to resolve the dispute by
the help of Mr Ray Wood and Mr Martin Rogers. If the dispute is not resolved within [ * ] of the first meeting of Mr Ray Wood and Mr. Martin Rogers, any Party may give the other a notice requiring that an attempt be made to resolve the dispute
with the help of a mediator to be appointed jointly by the Parties. If the Parties do not agree on a mediator within seven (7) days after such notice is given, the mediator is to be appointed by The Australian Commercial Disputes Centre
(“ACDC”). The mediation is to be conducted in accordance with the ACDC’s Rules for the Mediation of Commercial Disputes. Each of the Parties must pay an equal share of the fees and expenses the mediator is entitled to. 

 

	24.	 GOVERNING LAW AND JURISDICTION 

 This document is governed by the law of Victoria, Australia and the Parties submit to the non-exclusive jurisdiction of its courts. The Parties will not object to the exercise of jurisdiction by those
courts, either for forum non conveniens or on any other basis. 

  
 21/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	25.	 ENTIRE AGREEMENT 

 This Agreement contains the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements and understandings between the parties in connection with it.

  

	26.	 NO WAIVER 

 No failure to exercise nor any delay in exercising any right, power or remedy by a party operates as a waiver. A single or partial exercise of any right, power or remedy does not preclude any other or
further exercise of that or any other right, power or remedy. A waiver is not valid or binding on the party granting that waiver unless made in writing. 
  

	27.	 REMEDIES CUMULATIVE 

 The rights, powers and remedies provided to the parties in this Agreement are in addition to, and do not exclude or limit, any right, power or remedy provided by law or equity. 

 

	28.	 COUNTERPARTS 

 This Agreement may be executed in two counterparts. All counterparts together will be taken to constitute one instrument. If each party executes separate documents, this Agreement takes effect when the
parties exchange executed documents. 
  

	29.	 SEVERABILITY OF PROVISIONS 

 Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction is ineffective as to that jurisdiction to the extent of the prohibition or unenforceability. That does not
invalidate the remaining provisions of this Agreement nor affect the viability or enforceability of that provision in any other jurisdiction. 
  

	30.	 GST GENERAL PRINCIPLES 

  

	 	(a)	 CANCERVAC must pay GST on a Taxable Supply made to it under this Agreement, in addition to any consideration (excluding GST) that is payable for
that Taxable Supply. It must do so at the same time and in the same way as it is required to pay the consideration for the Taxable Supply. 

  

	 	(b)	 Without prejudice to (a) or (b), if the amount payable is calculated by reference to any costs, expenses or other liability incurred by a Party
(Payee), the relevant amount is the actual amount incurred by the Payee less the amount of any Input Tax Credit the Payee is entitled to claim in respect of that cost, expense or liability. 

 

	 	(c)	 The Parties must provide each other with all documentation, including tax invoices, required to claim any Input Tax Credit, set off, rebate or
refund for or in relation to any GST included in any payment made under this Agreement. CANCERVAC indemnifies CT against any loss resulting from CANCERVAC’s failure to provide such documentation. CANCERVAC warrants that it is registered for GST
and ABN purposes 

  
 22/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	 	 
and further indemnifies CT for any loss resulting from CANCERVAC’s failure to be registered for such purposes. 

 

	31.	 CHANGE IN CONTROL & STRUCTURE 

  

	 	(a)	 If either party undergoes any merger or reconstruction which results in the creation of a new legal entity to undertake the activities of that party
in relation to this Agreement, the new legal entity will assume responsibility for, and continue to perform, this Agreement unless the parties agree to a new agreement. 

 

	 	(b)	 This Agreement will endure to the benefit of each party’s permitted successors and assignees. 

 

	32.	 RELEASE OF INFORMATION 

  

	 	(a)	 The Parties acknowledge that the release of information to the public, including verbal and written communication, relating to the Services may be
beneficial to all Parties. Accordingly, the Parties will have the right to review and approve any such communications pursuant to Sub-Clause 32(a) 

  

	 	(b)	 Before any communication (such as media releases or other public releases of information) is released to an external third Party, the releasing
Party must send a complete copy of the communication to the other Parties by registered mail at least [ * ] prior to the release. All Parties must review the communication and provide its comments to the author. No such communications will be
released to an external third Party unless all Parties to this Agreement have given their prior approval in writing to the release of information or communication. This approval shall not be unreasonably withheld. All such releases and
communications must mention the respective contribution made by each Party. 

  

	 	(c)	 CANCERVAC must ensure that it or its nominees do not release information to the public, including verbal and written communication, relating to the
manufacture for the IND Trial or the Services unless that release has been approved by the parties in accordance with this clause 29. Of particular note is the avoidance of inappropriate public reference to matters involving manufacturing and the
TGA. 

  
 23/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTED BY THE PARTIES AS AN AGREEMENT 

 

					
	Signed for and on behalf of	 	)	 	
	CANCER VAC PTY. LTD.	 	)	 	
	By its duly authorised officer	 	)	 	
			
		 	)	 	
	Martin Roger	 	)	 	/s/ Martin Roger
	Director / Secretary	 	)	 	
		 	)	 	
	and	 	)	 	
		 	)	 	
	 	 	)	 	 
	Director	 	)	 	
		 	)	 	
		 	)	 	Date: 14th October 2009
			
	Signed for and on behalf of	 	)	 	
	CELL THERAPIES Pty. Ltd.	 	)	 	
	By its duly authorised officer	 	)	 	
		 	)	 	
		 	)	 	
	Raymond J Wood	 	)	 	/s/ Raymond J Wood
	Director	 	)	 	
		 	)	 	
	and	 	)	 	
		 	)	 	
	 	 	)	 	 
	Director	 	)	 	
		 	)	 	
		 	)	 	Date: 14th October 2009

  
 24/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 SCHEDULE 1 THE SERVICES 
 CT to undertake all tasks required to assume production responsibility for the Australian arm of the IND Trial and maintain support as requested for the USA arm of the IND Trial. 

 

	1.	 CT will provide the following services and others to be agreed between the parties from time to time: [ * ] 

 

	2.	 CT to undertake manufacturing comparability trials in collaboration with CANCERVAC’s nominated contract manufacturer in the USA, as specified
in the successful IND application. 

  

	3.	 CT undertake and manage all aspects of the cGMP manufacturing required for the execution of the Australian arm of the IND Trial. (CVacTM Phase
IIb trial) 

  

	4.	 CT to dedicate one clean room or its equivalent to CANCERVAC’s requirements for at least 12 months. 

 

	5.	 CT to maintain and develop CANCERVAC’s SOP’s and trial documentation as required for the IND Trial. 

 

	6.	 CT to appoint a manufacturing nominee (Production Manager) and quality nominee (Quality Manager) plus deputies as required for TGA regulatory
purposes. 

  
 25/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	7.	 CT to appoint a project coordinator/scientist and a suitably qualified laboratory technician who will be responsible for the day-to-day
manufacturing tasks including; scheduling, cell processing and record keeping. The coordinator/scientist will be the primary interface to CANCERVAC’s nominated Trial Manager and Authorised Representative. 

 

	8.	 CT to provide back up for the operational personnel as required during the Term. 

 

	9.	 By negotiation, CT to provide limited after hours personnel to meet the patient recruitment variables involved in the Australian arm of the IND
Trial 

  

	10.	 CT through the project co-ordinator, to maintain an open communication channel with CANCERVAC’s Trial Manager such that the cell processing
phase can be integrated with patient availability and Apheresis at CANCERVAC’s nominated collection point. 

  

	11.	 CT to support CANCERVAC in dealing with Australian and USA regulatory authorities including interaction with CANCERVAC’s USA regulatory
advisors. CT to maintain a watching brief over CANCERVAC’s dealing with Australian regulatory authorities. 

  

	12.	 [ * ] 

  
 26/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 SCHEDULE 2 CHARGES TO BE INCURRED BY CANCERVAC 

 

	1.	 FACILITY FEE 

 In exchange for a long term commitment, CT will provide guaranteed access to a fully supported clean room and the services described in Schedule 1 for a fixed fee per month: 

For a minimum twelve (12) month commitment, CT will charge $65,000 per calendar month ($780,000 pa). 

CT will invoice monthly in arrears 

Periodic Escalation 
 The Facility Fee will be for fixed for 12 months and is to be renegotiated on an annual basis by the Authorised Representatives as part of the annual review conducted under Clause 12. The Services Fee
negotiation will take into account that there can be evidence based increases in CT’s costs. Evidence can include published CPI index, variations in relevant agreements for labour award’s and variations in the charges for services or
goods. If the Authorised Representatives are unable to agree on a revised fee within 30 days of commencing the annual review then it will be referred for dispute resolution in accordance with Clause 23. If the parties are unable to agree on the
revised Services Fee following the completion of dispute resolution, the issue will be referred to an expert nominated by the President of the Institute of Chartered Accountants for binding determination. 

 

	2.	 CHARGES FOR CONSUMABLES AND IN-PROCESS TESTING 

[ * ] 
  

	3.	 CAPITAL EQUIPMENT PURCHASES DEDICATED TO THE PROJECT 

[ * ] 
  

	4.	 ARCBS QUALITY SYSTEMS 

 CT utilises the services of the ARCBS to provide [ * ]. CT expects to be able to integrate within the monthly facility fee any ARCBS’ quality support for CANCERVAC’s manufacturing within their
broader support agreement with ARCBS 
 CT reserves the right to negotiate with CANCERVAC to recover any
additional ARCBS costs if the quality management of the Project becomes significantly different from its current understanding of the requirements. Under such conditions CT would invoice only for the incremental cost of ARCBS’s support
for CANCERVAC’s changed requirements and with the Parties prior written agreement. 
  

	5.	 VALIDATION COSTS 

  
 27/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 [ * ] 

 

	6.	 TGA AUDIT AND LICENSE FEES 

 The TGA may elect to audit the manufacturing for the Australian arm of the IND Trial and may also apply a manufacturing license fee. 

If CT does incur any TGA charges that relate specifically to the manufacturing of the CANCERVAC materials then these
charges will be passed on to CANCERVAC by CT. 

  
 28/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	7.	 CONSULTING AND ADVISORY SERVICES 

 The Parties note that CT and CANCERVAC or PrimaBiomed may have other consulting arrangements in place for the provision of advisory services outside the scope of this Agreement, however: 

 

	 	7.1	 CT has considerable experience in managing the Australian regulatory environment and CANCERVAC may, at times, request CT’s assistance with the
management of its licensable activities. While it is understood and agreed by CT that a level of assistance for such purposes is inherent in the delivery of the Services there may be occasions where the time and resource allocation is beyond the
scope of the Services outlined in Schedule 1. 

 [ * ] 

 

	 	7.2	 In addition to fees specified in Schedule 2 #1 - #7, CANCERVAC may request specialist advice or support. When such support is requested and agreed
in writing the fees will be calculated monthly using the rate specified below. 

 [ * ]

  

	8.	 WORKING HOURS AND ADDITIONAL RATES 

 In setting the Services Fees, it has been assumed that an 8.30am to 5.00pm work day with occasional after hours or overtime work will meet requirements. If the trial requires continuous or exceptional
after-hours work a labour loading and the costs of extra use of the Facilities will be paid by CANCERVAC. [ * ] 

  
 29/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	9.	 CHARGES FOR ANCILLIARY SERVICES 

 In addition to the facility charge there will be a per-patient charge relating to: 
 [ * ] 
  

	11.	 STORAGE SERVICES (TO BE NEGOTIATED AS PROJECT REQUIREMENTS ARE IDENTIFIED) 

CT will provide the following controlled and monitored cryopreservation or refrigeration storage services in respect of
the following Materials and for the Storage Services Fee payable in the manner and at the times set out below: 
  

							
	 Material
	 	 Storage
Services
	 	 Storage
Services Fee
	  	Payable in the manner and a
the times set out as 
follows:

  
 30/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 SCHEDULE 3 INSURANCE 
 CANCERVAC Insurance Policies: 
 Insurance that is consistent with reasonable
commercial prudence to indemnify CANCERVAC against any liability which CANCERVAC may incur in relation to the Services or which CANCERVAC may incur under this Agreement (including professional indemnity insurance (including cover
for clinical trials), directors and officers insurance, public liability insurance, industrial special risks insurance and all other statutory insurances covering its employees, contractors, agents and operations). 

Product Liability Insurance policy covering liability to third parties for personal injury, disease and/or death arising from
CANCERVAC’s use of the Services or the use of CANCERVAC-supplied products in the provision of the Services. 
 The
insurance policies shall provide coverage for data loss or corruption or both and Loss of Material. 
 Public Liability
Insurance for an amount of cover not less than [ * ]. 
 Professional Indemnity Insurance for an amount of cover not less than [
* ]. 
 CT Insurance Policies: 
 Insurance that is consistent with reasonable commercial prudence to indemnify CT against any liability which CT may incur in relation to the Services or which CT may incur under this Agreement (including
professional indemnity insurance, directors and officers insurance, public liability insurance, industrial special risks insurance and all other statutory insurances covering its employees, contractors, agents and operations). 

Public Liability Insurance for an amount of cover not less than [ * ]. 

Professional Indemnity Insurance for an amount of cover not less than [ * ]. 

  
 31/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 SCHEDULE 4 TIMETABLE 
 [ * ] 
 As the Australian CRO identifies and recruits patients the Authorised
Representatives or their nominees will establish and maintain a timetable driven by the recruitment rate 

  
 32/32

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Agreement on the tasks and the Division of Responsibilities

 Exhibit 4.10 

 
 

 
  

	
	 Executive Services Agreement

	
	  

	  
 Prima Biomed
Limited

	 ACN 009 237 889

	
	 Martin Frederick Rogers

  

									
		  	718179_1	  		  	 McCabe Terrill Lawyers Ply Limited
	  	 T +61 2 9261 1211

		  		  		  	 ACN 122 850 033
	  	 F +61 2 9261 2336

		  		  		  	 130 Elizaheth Street (Level 14)
	  	 W www.mccabeterrill.com.au

		  		  		  	 Sydney NSW 2000
	  	
		  		  		  	 GPO Box 235 Sydney NSW 2001
	  	
		  		  		  	 DX 145 Sydney
	  	

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 1.
	 	 DEFINITION AND INTERPRETATION
	  	 	1	  
			
	 2.
	 	 APPOINTMENT AND POSITION
	  	 	4	  
			
	 3.
	 	 DUTIES
	  	 	5	  
			
	 4.
	 	 HOURS OF WORK
	  	 	6	  
			
	 5.
	 	 REMUNERATION
	  	 	7	  
			
	 6.
	 	 LEAVE ENTITLEMENTS
	  	 	8	  
			
	 7.
	 	 MEDICAL EXAMINATION
	  	 	8	  
			
	 8.
	 	 PRIVACY
	  	 	8	  
			
	 9.
	 	 CONFLICTS OF INTEREST
	  	 	9	  
			
	 10.
	 	 CONFIDENTIAL INFORMATION
	  	 	9	  
			
	 11.
	 	 INTELLECTUAL PROPERTY
	  	 	10	  
			
	 12.
	 	 RESTRAINT
	  	 	10	  
			
	 13.
	 	 TERMINATION
	  	 	12	  
			
	 14.
	 	 NOTICES
	  	 	15	  
			
	 15.
	 	 GENERAL
	  	 	15	  
		
	 SCHEDULE 1
	  	 	17	  
		
	 SCHEDULE 2
	  	 	18	  

  
 -i-

 Dated 
 Parties 
  

					
		  	 Prima Biomed Limited ACN 009 237 889

		  	 Address:
	  	 Suite 1, 1233 High Street, Armadale, VIC, 3143

		  	 Facsimile:
	  	 + 61 3 9822 7735

		  	 Attention:
	  	 The Board of Directors

		  	 (Company)
	  	
		
		  	Martin Frederick Rogers
		  	 Address:
	  	 313 Alison Road, Coogee, NSW, 2034

		  	 Facsimile:
	  	 N/A

		  	 (Executive)
	  	

 Background 
  

	A	 The Executive is currently employed by the Company as Chief Executive Officer and is a director of the Company. 

 

	B.	 The parties have agreed: 

  

	 	(i)	 the terms and conditions relating to his employment by the Company prior to the Commencement Date will no longer apply; and

  

	 	(ii)	 the Company will offer new terms and conditions of employment to the Executive, 

on the terms set out in this agreement and the Executive has accepted the offer. 

 

	1.	 Definition and Interpretation 

  

	1.1	 Definitions 

 In this agreement, unless the contrary intention appears, the following words have the following meanings: 
  

			
	 Term:
	  	Definition:
		
	 Board
	  	 the board of directors of the Company from time to time.

		
	 Business
	  	 the business carried on by the Company, being the business of developing a portfolio of biotechnology products related to the therapeutic area of cancer, and
such other business as the Company carries on during the course of the Executive’s employment.

			
	 Commencement Date
	  	 the date specified in Item 1 of Schedule 1.

		
	 Confidential Information
	  	 all information of which the Executive becomes aware or generates in the course of, or in connection with, his employment with the Company,
including:

		
		  	 (a)    information belonging to a third party;

		
		  	 (b)    customer and supplier lists;

		
		  	 (c)    trade secrets;

		
		  	 (d)    financial, accounting, marketing and technical information and
plans;

		
		  	 (e)    strategic plans and projections;

		
		  	 (f)     product ingredients, formulae, designs, specifications, ideas,
concepts and techniques;

		
		  	 (g)    technological processes, technology and equipment; and

		
		  	 (h)    any other information that the Executive is given which the Executive is
told is confidential, or that a reasonable person would expect from its nature to be confidential,

		
		  	 but excludes information that enters the public domain without any breach of this agreement.

		
	 Corporations Act
	  	 Corporations Act 2001 (Cth) as varied or replaced from time to time.

		
	 Fixed Termination Date
	  	 the date specified in Item 4 of Schedule 1.

		
	 FW Act
	  	 Fair Work Act 2009 (Cth) as varied or replaced from time to time.

		
	 Group
	  	 the Company and its Subsidiaries and Group Company means any one of them.

		
	Intellectual Property Rights	  	 all intellectual property rights created or otherwise brought into existence by the Executive solely or jointly with others (whether before or after the date
of this agreement):

		
		  	 (a)    in the course of, in connection with, or arising out of his employment with
the Company;

  
 2. 

			
	 	  	 (b)    using, to any extent, Confidential Information or the Group’s property, computer systems
or
         resources,

		
		  	 including any rights in respect of copyright, designs, circuit layouts, trade marks, trade secrets, know-how, patents, inventions and discoveries and all
other intellectual property as defined in Article 2 of the convention establishing the World Intellectual Property Organisation.

		
	 Moral Rights
	  	 (a)    the right of integrity of authorship;

		
		  	 (b)    the right of attribution of authorship of a work; and

		
		  	 (c)    the right not to have authorship of a work falsely
attributed,

		
		  	 and any other similar right capable of protection under the laws of any relevant jurisdiction.

		
	 Poor Performance
	  	 performance which is materially or persistently below the performance which a board of a comparable company would reasonably expect of a person in a
comparable role within the industry.

		
	 Position
	  	 the position specified in Item 2 of Schedule 1 and any other position to which the Executive is appointed in accordance with this
agreement.

		
	 Remuneration Package
	  	 the annual remuneration package to be provided by the Company to the Executive comprising the items set out in clause 5.1, and includes any variations as
agreed between the Executive and the Company, or as determined by the Company.

		
	 SGA Act
	  	 Superannuation Guarantee (Administration) Act 1992 (Cth) as varied or replaced from time to time.

		
	 SGC Act
	  	 Superannuation Guarantee Charge Act 1992 (Cth) as varied or replaced from time to time.

		
	 Subsidiaries
	  	 has the meaning given to that term in the Corporations Act.

  

	1.2	 Interpretation 

 In this agreement, unless the context otherwise requires: 
  

	 	(a)	 the singular includes the plural and vice versa; 

  
 3. 

	 	(b)	 another grammatical form of a defined word or expression has a corresponding meaning; 

 

	 	(c)	 a reference to a clause, paragraph or schedule is to a clause or paragraph of or schedule to this agreement and a reference to this agreement
includes any schedule or annexure; 

  

	 	(d)	 a reference to a document or instrument, includes the document or instrument as novated, altered, supplemented or replaced from time to time;

  

	 	(e)	 a reference to A$, $A, dollar or $ is to Australian currency; 

 

	 	(f)	 a reference to time is to New South Wales time; 

 

	 	(g)	 a reference to a party to this agreement, and a reference to a party to a document includes the party’s executors, administrators,
successors and permitted assigns and substitutes; 

  

	 	(h)	 a reference to a person includes a natural person, partnership, body corporate, association, governmental or local authority or agency or
other entity; 

  

	 	(i)	 a reference to a statute, ordinance, code or other law includes regulations and other instruments under it and consolidations, amendments,
re-enactments or replacements of any of them; 

  

	 	(j)	 the meaning of general words is not limited by specific examples introduced by including, for example or similar expressions;

  

	 	(k)	 a rule of construction does not apply to the disadvantage of a party because the party was responsible for the preparation of this agreement
or any part of it; and 

  

	 	(l)	 headings are for ease of reference only and do not affect interpretation. 

 

	2.	 Appointment and Position 

  

	2.1	 Employment 

 The Company employs the Executive in the Position in accordance with this agreement. 
  

	2.2	 Commencement Date 

 The Executive’s employment under this agreement commences on the Commencement Date and will continue until terminated in accordance with clause 13. 

 

	2.3	 Continuation of terms and conditions 

If the Executive’s position with the Company changes for any reason, then the terms of this agreement will continue
to apply unless expressly varied by the parties in writing. 

  
 4. 

	2.4	 Warranties 

 The Executive warrants that: 
  

	 	(a)	 by entering into this agreement and performing his duties under this agreement, he will not be in breach of any agreement with, or obligation
owed by him to, any third party; and 

  

	 	(b)	 he has disclosed everything to the Company which may be material to the Company’s decision to offer him employment under this agreement.

  

	3.	 Duties 

  

	3.1	 Specific duties 

  

	 	(a)	 The Executive must report to the Board and may be directed to perform both duties which are set out in Schedule 2 and such other duties and
responsibilities as are assigned to the Executive by the Board from time to time. 

  

	 	(b)	 The Executive must: 

  

	 	(i)	 perform to the best of his abilities and knowledge the duties assigned to him by the Board from time to time, whether during or outside the
Company’s business hours, at such places as the Company requires and for the benefit of whoever the Company directs (including any Group Company or a third party); 

 

	 	(ii)	 devote his full time and attention to the business of the Company and the Group; 

 

	 	(iii)	 serve the Company and the Group faithfully and diligently to the best of his ability and in accordance with the highest standards of
professionalism; 

  

	 	(iv)	 use all reasonable efforts to promote the interests of the Company and the Group; 

 

	 	(v)	 act in the best interests of the Company and the Group; 

 

	 	(vi)	 comply with all lawful directions of the Company; 

 

	 	(vii)	 comply with all laws, regulations and guidelines applicable to the Position and the duties assigned to him; 

 

	 	(viii)	 maintain professional awareness and continue to develop his skills and knowledge to ensure maintenance of best practice;

  

	 	(ix)	 comply with all Company policies; 

  
 5. 

	 	(x)	 fully disclose to the Board all material matters relevant to the operations of the Business; 

 

	 	(xi)	 attend all meetings of the Board; and 

  

	 	(xii)	 notify the Company of any other directorships held by him. 

 

	3.2	 Restrictions 

 The Executive must not: 
  

	 	(a)	 act in conflict with the best interests of the Company or the Group; 

 

	 	(b)	 engage in any conduct which has the potential to undermine the Board or the Company, such as engaging in conduct which might be considered to
be misleading; 

  

	 	(c)	 compete with the Company or the Group; or 

  

	 	(d)	 perform work for any person other than the Group without first obtaining the consent of the Company. 

 

	3.3	 Authority 

 The Executive acknowledges that he has no authority to bind, or make representations on behalf of, the Company except as expressly authorised by the Board from time to time. 

 

	3.4	 Directorship 

 The Executive acknowledges that the Company may require him to become a director of any Group Company. 
  

	4.	 Hours of Work 

  

	4.1	 Full-time 

 The Executive is employed on a full time basis and is required to work during the Company’s ordinary business hours, and for such additional hours as are necessary to perform his duties or required
by the Company. 
  

	4.2	 Acknowledgements 

 The Executive acknowledges and agrees that: 
  

	 	(a)	 he will be required to travel extensively, both domestically and overseas, to perform his duties; 

 

	 	(b)	 he may be required to work on public holidays; and 

  
 6. 

	 	(c)	 working additional hours, including while travelling and on public holidays, is part of his role and that this has been taken into account in
setting the Remuneration Package. 

  

	5.	 Remuneration 

  

	5.1	 Remuneration Package 

  

	 	(a)	 In consideration of the Executive performing his duties under this agreement, the Company will provide the Executive a Remuneration Package
comprising the salary and other benefits specified in Item 3 of Schedule 1. 

  

	 	(b)	 The Executive acknowledges and agrees that the Remuneration Package is subject to the deduction, or withholding of any amounts on account of,
any applicable taxes. 

  

	5.2	 Payment 

 The Executive’s salary will be paid by equal monthly installments in arrears by electronic funds transfer. 
  

	5.3	 Superannuation 

 The Executive’s salary includes the minimum level of superannuation contributions which the Company must make for the Executive so as not to be liable to pay a charge under the SGA Act and the SGC
Act. The Company will make such contributions into the superannuation fund the Executive chooses from time to time in accordance with the SGA Act. If the Executive does not choose such a fund, the Company will make such contributions into its
default superannuation fund from time to time. 
  

	5.4	 Review 

 The Company will review the Remuneration Package on an annual basis. 
  

	5.5	 Director’s remuneration 

 The Remuneration Package is paid in respect of all services provided by the Executive to the Company under this agreement, including services in connection with holding office as a director of any Group
Company. No separate amount is payable by the Company to the Executive in respect of his services as a director of any Group Company. 
  

	5.6	 Reimbursement of expenses 

 The Company will pay for or reimburse the Executive for out-of-pocket expenses properly incurred by the Executive in connection with the performance of his duties under this agreement, subject to the
Executive providing the Company with appropriate receipts and invoices substantiating each expense in accordance with the Group’s policies and procedures. 

  
 7. 

	5.7	 Deductions 

 To the extent permitted by law, the Executive irrevocably authorises the Company to deduct from the Remuneration Package any amounts which the Executive owes on any account to the Company. 

 

	6.	 Leave Entitlements 

  

	6.1	 Annual Leave 

  

	 	(a)	 The Executive is entitled to 20 days paid annual leave per year of service in accordance with applicable law. 

 

	 	(b)	 There is no entitlement to leave loading in respect to annual leave. 

 

	 	(c)	 The Company may direct the Executive to take annual leave on one month’s notice. 

 

	6.2	 Personal/Carer’s Leave 

  

	 	(a)	 The Executive is entitled to sick leave, carer’s leave and/or compassionate leave in accordance with applicable law.

  

	 	(b)	 No payment in lieu of sick leave, carer’s leave or compassionate leave will be made, either on termination or otherwise.

  

	6.3	 Parental Leave 

 The Executive is entitled to parental leave in accordance with applicable law. 
  

	6.4	 Long Service Leave 

 The Executive will be entitled to long service leave in accordance with applicable law. 
  

	7.	 Medical examination 

 The Board may require the Executive to be examined by a medical practitioner nominated by the Company, who will provide a report to the Company. 

 

	8.	 Privacy 

 The Executive consents to each Group Company collecting, using and disclosing personal and sensitive information (as those terms are defined in the Privacy Act 1998 (Cth)) concerning the Executive
for any purpose relating to his employment by the Company. 

  
 8. 

	9.	 Conflicts of Interest 

  

	9.1	 Disclosure of interests 

 The Executive must declare to the Company the nature of any interests that the Executive may have directly or indirectly which might or might reasonably be expected to then conflict with the
Executive’s duties to the Company. 
  

	9.2	 Exchange traded stock 

 The obligations imposed by this clause 9 do not prevent the Executive holding shares in any company listed on any recognised stock exchange. 

 

	10.	 Confidential Information 

  

	10.1	 Access 

 The Executive acknowledges that, having regard to the Position, he will have access to Confidential Information and that disclosure of any Confidential Information could materially harm the Group.

  

	10.2	 Not to divulge 

 The Executive must keep confidential all Confidential Information and must not, either during or after termination of the Executive’s employment with the Company, disclose to any person or use any
Confidential Information except: 
  

	 	(a)	 to the extent reasonably required in the performance of the Executive’s duties under this agreement; or 

 

	 	(b)	 as required by law. 

  

	10.3	 Notification 

 The Executive must immediately notify the Company of any suspected or actual unauthorised use, copying or disclosure of Confidential Information. 

 

	10.4	 Limitation of disclosure 

 Before the Executive discloses any Confidential Information under any law the Executive must provide the Company with: 
  

	 	(a)	 sufficient notice of the disclosure to be made; and 

 

	 	(b)	 all assistance and co-operation which the Company considers necessary in regard to such disclosure. 

  
 9. 

	10.5	 Survival 

 This clause 10 survives termination of this agreement. 
  

	11.	 Intellectual Property 

  

	11.1	 Assignment of Intellectual Property Rights 

The Executive assigns to the Company all existing and future right, title and interests in and to all Intellectual
Property Rights. 
  

	11.2	 Assistance 

 The Executive must do all things reasonably requested by the Company to enable the Company to exploit and further assure the rights assigned, and consents given, under clause 11.1. 

 

	11.3	 Moral Rights 

 The Executive: 
  

	 	(a)	 to the extent permitted by law, irrevocably waives any Moral Rights he has in respect of all Intellectual Property Rights; and

  

	 	(b)	 voluntarily and unconditionally consents to any acts or omissions by the Company, or other persons authorised by the Company, which would
otherwise infringe the Moral Rights he has in respect of any Intellectual Property Rights. 

  

	11.4	 Survival 

 This clause 11 survives termination of this agreement. 
  

	12.	 Restraint 

  

	12.1	 Clause 12 definitions 

 In this clause 12 (and any other provision of this agreement which relates to this clause 12 or its subject matter), unless the context otherwise requires: 

 

	 	(a)	 Engage in means to participate, assist or otherwise be directly or indirectly involved in, including as a member, shareholder, unitholder,
director, consultant, adviser, contractor, principal, agent, manager, employee, beneficiary, partner, associate, trustee or financier; 

  

	 	(b)	 Restraint Area means: 

  

	 	(i)	 anywhere in the world, or if such area is determined to be invalid or unenforceable by a court of competent jurisdiction;

  
 10.

	 	(ii)	 Australia and USA, or if such area if determined to be invalid or unenforceable by a court of competent jurisdiction;

  

	 	(iii)	 Australia, or if such area if determined to be invalid or unenforceable by a court of competent jurisdiction; 

 

	 	(iv)	 New South Wales; Queensland and Victoria, or if such area if determined to be invalid or unenforceable by a court of competent jurisdiction;
and 

  

	 	(v)	 New South Wales. 

  

	 	(c)	 Restrained Business means a business or operation substantially the same or similar to, or competitive with, the Business.

  

	 	(d)	 Restraint Period means the period commencing on the date of termination of the Executive’s employment and continuing for a period of:

  

	 	(i)	 12 months, or if such period is determined to be invalid or unenforceable by a court of competent jurisdiction; 

 

	 	(ii)	 6 months, or if such period is determined to be invalid or unenforceable by a court of competent jurisdiction; and

  

	 	(iii)	 3 months. 

  

	12.2	 Restraint obligations 

 During the term of this agreement, and for the Restraint Period, the Executive must not, either directly, indirectly or as a result of contact by any other party, in the Restraint Area, without the prior
written consent of the Company (which it may withhold in its absolute discretion): 
  

	 	(a)	 Engage in a Restrained Business; 

  

	 	(b)	 take any action to prepare to Engage in a Restrained Business; 

 

	 	(c)	 be concerned or interested (directly or indirectly, or through any interposed body corporate, trust, principal, agent, shareholder,
beneficiary, or as an independent contractor or in any other capacity) in a Restrained Business; 

  

	 	(d)	 solicit, canvas or secure the custom of any person who is, or was a customer, identified prospective customer, supplier, distributor or
licensee of any Group Company with whom the Executive dealt at any time during the last 12 months of the Executive’s employment with the Company for the purpose of transacting business relating to the Restrained Business;

  
 11.

	 	(e)	 accept any instructions to perform any work relating to the Restrained Business for any person who is, or was a customer, identified
prospective customer, supplier, distributor or licensee of any Group Company; or 

  

	 	(f)	 induce or attempt to induce an employee of any Group Company to terminate his or his employment with the Group Company.

  

	12.3	 Independence of restraints 

 Each of the restraint obligations imposed by this clause 12 (which results from the combinations of Restrained Business and Restraint Areas) is a separate and independent obligation from the other
restraint obligations imposed (although they are cumulative in effect). 
  

	12.4	 Reasonableness of restraint 

 The Executive acknowledges and agrees that each of the restraint obligations imposed by this clause 12 is reasonable in its extent (as to all of duration, geographical area and restrained conduct) having
regard to the interests of each party to this agreement and extends no further (in any respect) than is reasonably necessary and is solely to protect the Company’s legitimate interests. 

 

	12.5	 Legal advice 

 Each party acknowledges that in relation to this clause 12 it has received legal advice or has had the opportunity of obtaining legal advice. 

 

	12.6	 Notification to prospective employer 

The Executive will notify any prospective employer of the terms of the restrictions undertaken by him in this agreement.

  

	12.7	 Injunction 

 Each party to this agreement acknowledges that monetary damages alone would not be adequate compensation to the Company for a breach of clause 12 and that the Company is entitled to seek an injunction or
other equitable relief from a Court of competent jurisdiction if the Executive fails to comply or threatens to fail to comply with clause 12 or the Company has reason to believe the Executive will not comply with clause 12. 

 

	12.8	 Survival 

 This clause 12 survives termination of this agreement. 
  

	13.	 Termination 

  

	13.1	 Termination on notice 

  

	 	(a)	 Subject to clause 13.2, the Executive’s employment may be terminated: 

  
 12.

	 	(i)	 by the Executive, at any time, giving to the Company six month’s notice in writing; or 

 

	 	(ii)	 by the Company: 

  

	 	(A)	 on or after the Fixed Termination Date, giving to the Executive six month’s notice in writing for any reason;

  

	 	(B)	 at any time, if the Executive is subject to Poor Performance, by providing the minimum period of statutory notice of termination under the FW
Act; or 

  

	 	(C)	 electing, in its absolute discretion, to make a payment to the Executive equal to the Executive’s salary in lieu of any period of
notice, or the unexpired part of any period of notice, to be given under clauses 13.1(a)(ii)(A) or 13.1(a)(ii)(B). 

  

	 	(b)	 If the Company does elect to make a payment to the Executive under clause 13.1(a)(ii)(C), then the Executive’s employment terminates on
the date the Company notifies the Executive of the election. 

  

	13.2	 Summary dismissal 

 The Executive’s employment may be summarily terminated by the Company at any time without notice and without payment of any compensation in lieu of notice if the Executive: 

 

	 	(a)	 is guilty of serious misconduct, fraud, dishonesty, wilful breach of duty, or of a serious or persistent breach of the Executive’s
employment obligations; 

  

	 	(b)	 breaches any material provision of this agreement, including clauses 3.1, 3.2 or 10; 

 

	 	(c)	 is found guilty by a court of a serious criminal office which in the reasonable opinion of the Company might injure the reputation of the
Group; 

  

	 	(d)	 is unable to perform the inherent requirements of his position for a period of six months or longer (other than by reason of partial or total
and permanent disability, as supported by independent medical opinion or for any other justifiable cause outside the Executive’s control); or 

  

	 	(e)	 becomes bankrupt or enters into a composition or arrangement with his creditors. 

 

	13.3	 Gardening leave 

 During the notice period provided for by clause 13.1, or while the Company is investigating any matter which the Company believes could lead to the Company

  
 13.

 
exercising its rights under clause 13.2 or taking other disciplinary action, the Company may require the Executive: 

 

	 	(a)	 not to enter or access any Group Company’s premises; 

 

	 	(b)	 to perform duties which are different from those which the Executive was required to perform during his employment with the Company;

  

	 	(c)	 not to contact or have any communications with any customer, client, employee or officer of the Group; or 

 

	 	(d)	 to do any combination of the above things. 

 

	13.4	 Resignation as a director 

 If, on termination of this agreement, the Executive is a director of any Group Company the Executive must immediately resign as a director of that Group Company. 

 

	13.5	 Return of Company property 

  

	 	(a)	 If the Executive’s employment is terminated for any reason, the Executive must immediately return to the Company any property of any
Group Company, including all documents, software, computers, credit cards, keys, mobile telephones, security passes and vehicles. 

  

	 	(b)	 The Executive is not entitled to retain a copy of a document referred to in clause 13.5(a). 

 

	13.6	 Accrued rights 

 Termination under this clause 13 does not affect any accrued rights or remedies of either party. 
  

	13.7	 Limitation of payments and benefits 

  

	 	(a)	 If the payments and benefits otherwise payable or due to the Executive as a result of the termination of the Executive’s employment or
this agreement would exceed the maximum amount or value which the Company is permitted, without shareholder approval, to pay or provide to the Executive (in the circumstances at that time) under the Corporations Act (Maximum Amount), then,
notwithstanding any other provisions of this agreement, the payments or benefits payable or due to the Executive as a result of the termination of the Executive’s employment or this agreement will be reduced as determined by the Company so that
the amount of the payments or value of the benefits, having regard to the payments and the value of the benefits (if any) already made or provided or payable or to be provided in connection with the Executive’s retirement from board or
managerial office (as that term is defined in the Corporations Act) in any Group Company does not exceed the Maximum Amount. 

  
 14.

	 	(b)	 Without limiting clause 13.7(a), no payment will be made to, or benefit conferred on, the Executive under this agreement to the extent such
payment would cause any Group Company to breach the ASX Listing Rules, the Corporations Act or any applicable law. 

  

	14.	 Notices 

  

	14.1	 Service and notices 

 A notice, demand, consent, approval or communication under this agreement (Notice) must be: 
  

	 	(a)	 in writing, in English and signed by a person duly authorised by the sender; and 

 

	 	(b)	 hand delivered or sent by prepaid post or facsimile to the recipient’s address for Notices specified in the Parties section of this
agreement, as varied by any Notice given by the recipient to the sender. 

  

	14.2	 Effective on receipt 

 A Notice given in accordance with clause 13.1 takes effect when taken to be received (or at a later time specified in it), and is taken to be received: 

 

	 	(a)	 if hand delivered, on delivery; 

  

	 	(b)	 if sent by prepaid post, on the second Business Day after the date of posting; 

 

	 	(c)	 if sent by facsimile, when the sender’s facsimile system generates a message confirming successful transmission of the entire Notice,

 but if the delivery, receipt or transmission is not on a Business Day or is after 5.00pm on
a Business Day, the Notice is taken to be received at 9.00am on the next Business Day. 
  

	15.	 General 

  

	15.1	 Entire agreement 

 This agreement constitutes the entire agreement between the parties in relation to its subject matter. All prior discussions, undertakings, agreements, representations, warranties and indemnities in
relation to that subject matter are replaced by this agreement and have no further effect. 
  

	15.2	 Amendment 

 This agreement may not be amended or varied unless the amendment or variation is in writing signed by all parties. 

  
 15.

	15.3	 Costs 

 Each party must pay its own costs and expenses in relation to the negotiation, preparation and execution of this agreement. 

 

	15.4	 Severability 

 Part or all of any provision of this agreement that is illegal or unenforceable will be severed from this agreement and will not affect the continued operation of the remaining provisions of this
agreement. 
  

	15.5	 Waiver 

 Waiver of any power or right under this agreement must be in writing signed by the party entitled to the benefit of that power or right and is effective only to the extent set out in that written waiver.

  

	15.6	 Governing law and jurisdiction 

 This agreement will be governed by and construed in accordance with the laws in force in the State of New South Wales and each party submits to the non-exclusive jurisdiction of the courts of that State.

  
 16.

 Schedule 1 
 Remuneration 
  

 
  

			
		
	 Item 1: Commencement Date
	  	 1 January 2011

		
	 Item 2: Position
	  	 CEO

		
	 Item 3: Salary and other benefits
	  	 A total remuneration package of $315,000 per annum, inclusive of superannuation.

 
 The employer superannuation contributions will be
$22,000 to 30 June 2011, and $25,000 per annum thereafter.

		
	 Item 4: Fixed Termination Date
	  	 31 December 2012

  
 17.

 Schedule 2 
 Duties 
  
  

The Executive must devote such of the Executive’s time, attention and skill to the Company during the Term as required for the
proper performance of the following duties: 
  

	 	•	 	 provide support, mentoring and guidance to the Company’s senior employees’; 

 

	 	•	 	 prepare and settle agendas for all Board meetings; 

 

	 	•	 	 assist with regulatory; 

  

	 	•	 	 operate the Business in accordance with the objectives of the Company; 

 

	 	•	 	 protect and enhance the goodwill and reputation of the Company and the Business; 

 

	 	•	 	 monitor and direct the Company’s day to day activities and overall operations to promote and extend the performance of the Business and the
Company; 

  

	 	•	 	 conduct meetings and negotiate terms with companies and individuals with whom the Company will enter into agreements; 

 

	 	•	 	 prepare the business plan and budget; 

  

	 	•	 	 conduct the Business in compliance with the approved budget and approved business Plan; 

 

	 	•	 	 obtain approval from the Board for any expenditure outside of the budget; 

 

	 	•	 	 engage contractors, sales people, technicians and other personnel required for the expansion of the Business and have overall control of the
Business; 

  

	 	•	 	 leadership and development of the Company’s staff in order to meet operating needs in the immediate and longer term;

  

	 	•	 	 manage the provision of legal, tax and accounting services to the Business and the Company; 

 

	 	•	 	 protect the Intellectual Property Rights of the Company; 

 

	 	•	 	 supervise and manage the Company’s business in accordance with Board approved business plans and budgets; 

 

	 	•	 	 oversee projects; 

  
 18.

	 	•	 	 procure the provision of monthly progress, financial and cashflow reports to the Company; and other information as reasonably requested by the Board
from time to time; and 

  

	 	•	 	 keep accurate and complete records of all matters relating to the Company and the Business and retaining such records, as well as all receipts and
vouchers, for inspection by the Company if requested. 

  
 19.

									
	 EXECUTED as an agreement
  

EXECUTED by PRIMA BIOMED
	 		 	 )
	 		  	
	 LIMITED CAN 009 237 889 in
	 		 	 )
	 		  	
	 accordance with section 127 of the
	 		 	 )
	 		  	
	 Corporations Act 2001 
	 		 	 )
	 		  	
		 		 	 )
	 		  	
					
	 /s/ Lucinda Turnbull
	 		 		 		  	 /s/ Albert Wong

	 Signature of Director
	 		 		 		  	 Signature of Director

					
	 Lucinda Turnbull
	 		 		 		  	 Albert Wong

	 Name of Director
	 		 		 		  	 Name of Director

					
	 SIGNED by MARTIN FREDERICK 
	 		 	 )
	 		  	
	 ROGERS in the presence of:
	 		 	 )
	 		  	
		 		 	 )
	 		  	
		 		 	 )
	 		  	
		 		 	 )
	 		  	
					
	 /s/ Albert Wong
	 		 		 		  	 /s/ Martin Frederick Rogers

	 Signature of Witness
	 		 		 		  	Martin Frederick Rogers
					
	 Albert Wong
	 		 		 		  	
	 Name of Witness

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]